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Settings. Despite the limited diagnostic utility of AgNORs (argyrophilic nucleolar organiser region-associated proteins) for
individual breast lesions, AgNOR analysis bears a signiﬁcant potential for characterizing cell proliferative activity of breast lesions.
Methodology. The present study investigated the relationship between mean AgNORs count and immunohistochemical expression
of ER, PR, HER2/neu, and p53 in breast carcinoma in serial paraﬃn sections from 137 breast carcinomas. Twenty control cases
of benign breast lesions were included. Results. Mean AgNOR counts correlated signiﬁcantly inversely with hormone estrogen
receptors (ER), Progesterone receptors (PR), and p53 immunohistochemical expression, denoting P values of 0.05, 0.01, and
0.001, respectively. No signiﬁcant correlation was found between mean AgNOR counts and HER2/neu, P = 0.9. Mean AgNOR
count was signiﬁcantly higher in grade II tumor cells. We conclude that mean AgNOR counts correlate with ER, PR, and P53
tumor markers in breast carcinomas. Conclusion. We recommend the use of mean AgNOR count for accurate reporting of breast
carcinomas, as well as prediction of ER, PR, and P53 in routine paraﬃns e c t i o n s .
1.Introduction
Breast cancer is the top cancer in women both in the
developed and the developing world [1]. Breast cancer
survival rates vary greatly worldwide, ranging from 80%
or over in North America, Sweden, and Japan to around
60% in middle-income countries and below 40% in low-
incomecountries[2].Thelowsurvivalratesinlessdeveloped
countries can be explained mainly by the lack of early detec-
tion programmes, resulting in a high proportion of women
presenting with late-stage disease, as well as by the lack of
adequate diagnosis and overall management facilities [1].
Since breast cancer is one of the hormone-dependent
tumors much attention has been paid to the relationship
between ER and PR and breast cancer. The study by Blanco
et al. [3] showed that ER+ PR+ patients had better prog-
nosis than ER− PR− patients. In late 1970s and early 1980s,
the measurement of ER as well as PR became standard
practice in the prediction of the outcome of breast cancer
patients [4].
Early observations after the identiﬁcation of the p53
protein suggested that p53 functioned as an oncogene. In
fact, it does, but only in the mutated form. In the late 1980s,
however, several discoveries proved that the normal function
of p53 was antioncogenic. One of the several functions of
the normal p53 gene is suppression of cell proliferation.
When DNA is damaged, p53 inhibits the progression of cell
cycle from G1 to the S-phase or during S-phase [5, 6]. The
mutation of the p53 gene has been detected in almost 50% of
human cancers including breast cancer [7, 8]. Several studies
demonstrated that mutations of p53 or increased nuclear
expression of p53 protein is a prognostic factors in breast
cancer and associated with worse prognosis [9, 10].
HER2/neu proto-oncogene encodes a 185-KDa trans-
membrane glycosylated epidermal growth factor receptor2 Pathology Research International
that contains an extracellular domain and has intracellular
tyrosine kinase activity [11]. Ampliﬁcation of the HER2/neu
gene and overexpression of its protein are known to be
characteristic of many breast cancers. Several studies have
correlated the overexpression of the HER2/neu oncogene
with poor prognosis in breast cancer patients [12, 13],
Nucleolar organiser regions (NORs) are loops of DNA
that are responsible for ribosomal RNA (rRNA) transcrip-
tion. They are located in the nucleoli of cells and in the
chromosomes 13–15 and 21, 22 in association with proteins
[14]. As rRNA molecules are the main sites of protein
synthesis, it follows that the number of NORs in each cell
nucleus reﬂects cellular activity [15]. The number and size of
AgNORs can be assessed following staining of tissues or cells
with silver stains [16].
AgNORs is correlate with the proliferative activity of
neoplasms. Increased AgNOR counts may reﬂect increased
proliferative activity of cells [17, 18]. AgNOR counts have
been studied in breast carcinoma, but the results have been
conﬂicting. Some studies have demonstrated that quan-
titative analysis of AgNORs yields a prognostic factor in
breast cancer [19].
AgNOR increasingly applied in histopathology research
followingsuggestionsthattheremaybeapossibleassociation
between high AgNOR counts and malignant transformation
[20, 21]. It is interesting to hypothesize, therefore, that the
numbers, the shape, and the distribution of AgNORs within
the nucleus might be of potential use in predicting behavior
in breast carcinomas. In this study, we investigated the
usefulness of the AgNOR technique in assessing the ER, PR,
P53, and HER2/neu tumor markers in breast carcinomas.
2.MaterialsandMethods
One hundred and ﬁfty seven formalin-ﬁxed, paraﬃn-
embedded tissue block samples from the breast lesions
(including 124 cases of invasive ductal carcinoma, 13 in situ
ductal carcinomas, and 20 cases of benign breast lesions)
were investigated in this study.
All biopsies were obtained from females with breast
lesions, their ages ranging from 16 to 80 years with mean
age of 43 years old. Patients with breast cancer (n = 137)
ascertained as cases, and those with benign breast lesions
w e r ea s c e r t a i n e da sc o n t r o l s( n = 20).
2.1. Sample Processing. Serial sections on poly-L-lysine-
coated slides for immunohistochemistry (IHC) and one
section on a regular slide for hematoxylin and eosin stain
were prepared from each case. The Immunohistochemical
staining: immunohistochemistry staining was performed as
described previously [22, 23]. Slides were heated overnight
at 56◦C, followed by deparaﬃnization through graded
ethyl alcohols and rehydration. Before immunostaining with
antibodies, the tissues were treated with 10mM sodium
citrate buﬀer at 1001C for 15 minutes for antigenic retrieval.
The samples were incubated with 0.3% hydrogen perox-
ide (Merck, Germany) in methanol for 30 minutes to
inhibit endogenous peroxidase activity, washed 3 times with
phosphate-buﬀered saline (PBS). After blocking nonspeciﬁc
sites with horse normal serum (DAKO, Denmark) diluted in
phosphate buﬀer (PBS), the slides were rinsed with distill
water 2 × 5 minutes in PBS. Primary antibodies were
incubated for 8 hours in a humidity chamber using the
following dilutions: p53 (clone DO-7, titer 1:50, Dako,
Denmark), HER-2/neu (titer 1:50, Dako, Denmark), ER
(clone 1D5, Dako, Denmark), and PR (clone PgR 636, Dako,
Denmark), was performed by applying the avidin-biotin-
Peroxidase complex method. After 2 × 5 minutes in rinse
PBS, secondary antibody (LSAB2, DAKO) was incubated for
30 minutes in the same chamber. Detection of the primary
antibody was obtained using the Strepto ABC, LSAB2 system
(DAKO) according to the manufacture instructions. The
slides were counter stained with hematoxylin, mounted and
analyzed with light microscope. All slides were performed at
the same time and submitted to standard methods. Known
positive and negative cases were used as external controls.
Two investigators (M. A. Al-Adhraei and H. G. Ahmed)
evaluated the slides independently. Positive expression for
each tumor marker was deﬁned as in the literature: ER and
PR were considered positive when >10% of the nuclei were
stained in 10 high power ﬁeld (HPF) [24, 25]. The HER-
2/neu was considered negative when it had score 0 and +1
and positive with score +2 and +3. To be considered as +2
and +3, the cellular membrane should be completely stained
in more than 10% of the tumor cells. Cells without staining
or with weak staining in part of the cell membrane and in
less than 10% of the tumor cells were considered negative
[26]. P53 was considered positive when >5% of the nuclei
were stained in 10 HPF [27].
2.2. AgNOR Staining Method. The sections were stained
according to the AgNOR method. Working solution was
freshly prepared by mixing one volume of 2% gelatin in
1% formic acid solution and two volumes of 50% aqueous
silver nitrate solution. All sections were incubated with this
silver solution for 30 minutes at room temperature in a
dark medium, and they were protected in the dark until
each slide was analyzed. Two investigators, blind to the
study groups, analyzed the silver-stained cells under light
microscope(OlympusBX-51,Japan)at1000xmagniﬁcation.
All sections were screened horizontally from left to right,
and AgNORs were counted in the nuclei of the ﬁrst 50
nucleated cells. Cells with pyknotic nuclei were not counted.
TheAgNORcountwasmadeadoptingthemethoddescribed
by Ahmed and Babiker [28].
AgNORs, which were visible as black-dark brown dots
located within the nuclei of the cells, were counted; over-
lapped black dots were counted as one structure.
2.3. Statistical Analysis. SPSS version 17 statistical software
wasusedforstatisticalanalysis.Thenumericresults(AgNOR
counts and tumor markers) were expressed as mean ± SD,
and the 95% conﬁdence intervals (CIs) of the means were
calculated. The X2 test was used to compare the diﬀerences
in categorical variables between the groups. Relationships
between variables were analyzed using Pearson’s correlation
analysis. A P<0.05 was considered statistically signiﬁcant.Pathology Research International 3
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Figure 1: Description of mean AgNORs counts in benign and ma-
lignant groups.
Figure 2: AgNORs dots in IDC.
3. Results
AgNORs were clearly visible on light microscopical exam-
ination as black silver binding dots within nuclei stained
orange. AgNOR silver stain was applied in all benign and
malignant tumors. As it is explored in Figure 1, there is
a signiﬁcant diﬀerences in the mean of AgNORs counting
among malignant (mean = 2.57) and benign (mean =1.26)
(P<0.0001) study subjects, (see Figures 2, 3,a n d4).
Details of mean AgNORs counting and association with
other variables were summarized in Table 1. In malignant
group, with age at diagnosis , AgNORs counts did not show
signiﬁcant diﬀerences (P = 0.183). AgNORs counts with
other prognostic markers were evaluated, where counts of
these nuclear loops were signiﬁcantly diﬀerent with ER, PR,
andp53expressionbutnotwithHER2.AgNORscountswere
signiﬁcantly inversely associated with PR expression (P =
0.010) and in to some extent with ER expression (P = 0.053)
(ER +ve = 2.45 versus ER −ve = 2.71 and PR +ve = 2.36
versus PR −ve = 2.71). With p53, AgNORs mean counts
showed positive signiﬁcant association (P = 0.001) (p53 +ve
= 2.81 versus p53 −ve = 2.36). Tumor grade was signiﬁcantly
diﬀerent by AgNORs mean counting (P = 0.022) (grade I
= 2.66 versus grade III = 3.41; P = 0.001) while histological
Figure 3: AgNORs dots in IDC.
Figure 4: AgNORs dots in benign breast tumor.
type (invasive ductal carcinoma (IDC) and NonIDC) (P =
0.351), tumor size (P = 0.747), and lymph node status (P =
0.681) did not show any signiﬁcant diﬀerences in AgNORs
mean counting.
4. Discussion
The management of breast carcinoma depends on a number
of morphological and biological factors. These include
tumor type and grade the presence of local invasion and
lymph node metastases, the degree and proportion of nuclei
showing atypia (e.g., hyperchromatism, pleomorphism, and
mitotic activity), and the presence or absence of particular
tumor markers (e.g., ER and PR receptor status) [14].
The increased number of AgNOR dots is, in many cases,
considered to be of diagnostic and prognostic signiﬁcance
in tumor pathology, because of its direct relationship to the
frequency of cell proliferation and other requirements for
ribosome biogenesis [29]. Although the number of AgNORs
isincreasedinmalignancy,someworkersconsidereditasnot
diagnostic due to overlap with benign proliferation [30]. It
seems that although the number of AgNORs per cell is not
discriminatory enough on its own to determine malignancy,
the addition of size or area measurements using image
analysis gives improved diagnostic and prognostic speciﬁcity
[31, 32].
In the present study, it can be seen that mean AgNOR
count among the malignant cases is signiﬁcantly higher
than in the benign, which is a similar ﬁnding with the study4 Pathology Research International
Table 1: Association between mean AgNOR counts and diﬀerent variables.
Variables AgNORs count Mean of
AgNORs P value
≤2d o t s / c e l l >2d o t s / c e l l
Age
≤40 15 36 2.49 0.73
>40 23 63 2.67
ER +ve 26 47 2.45 0.05
−ve 12 52 2.71
PR +ve 22 32 2.36 0.010
−ve 16 67 2.71
HER2 +ve 8 27 2.58 0.997
−ve 30 72 2.57
P53 +ve 14 52 2.81 0.001
−ve 24 47 2.36
Histological type IDC 32 92 2.60 0.351
NIDC 6 7 2.38
Tumor size
<2cm 1 6 2.80
0.747 2–5cm 20 54 2.50
>5cm 6 19 2.66
Tumor grade
Grade I 7 15 2.40
0.022 Grade II 16 32 2.37
Grade III 0 17 3.41
Lymph node
status
−ve LN 4 16 2.44 0.681
+ve LN 18 43 2.52
of Guski et al. [33]. They determined the diagnostic and
prognostic value of AgNORs in atypical ductal hyperplasia
(ADH), ductal carcinoma in situ (DCIS), and microinvasive
ductal carcinoma (MDCA) of the breast. AgNOR number
and total AgNOR area increased from ADH to DCIS.
The highest values were recorded in cases of DCIS with
microinvasion. Diﬀerences between ADH and intraductal or
microinvasive ductal carcinoma were statistically signiﬁcant.
Within the group of intraductal carcinomas, the lowest
values were measured in the solid type and highest values in
the comedo type.
Although signiﬁcant inverse correlation was reported
between proliferation markers and histopathological grade
inaserialof36breastcarcinomas[34],wefoundasigniﬁcant
positive association between tumor grade and AgNORs (P =
0.001). However, similar ﬁndings were reported by several
studies [33–35].
In the present study, signiﬁcant inverse correlations
were found between proliferation markers and ER and PR
receptor status and such ﬁndings were previously reported
[33, 34] .T h er e l a t i o nb e t w e e nE Rr e c e p t o r sa n dA g N O R s
within breast cancer cells was analyzed in 49 invasive breast
carcinomas by digital image analysis. A higher AgNOR
content in ER-negative cells and a special clustering phe-
nomenoninER-positivetumorcellswerefound.Correlation
withothercriteriaofmalignantpotentialcouldbeexclusively
demonstrated for ER-negative cells. ER-negative cells of
breastcancercanbecharacterizedasthemoremalignantand
possibly prognosis-dictating cell fraction. Thus, ER-negative
cells probably contribute more to the progression of the
tumor disease and furthermore to the prognosis than ER-
positive cells [36].
The oncosuppressor proteins pRb and p53 may exert a
key role in coupling growth and proliferation by controlling
both ribosome biogenesis and cell cycle progression. In
the present study, we found a signiﬁcant positive relation
between AgNOR and P53. The AgNOR response in human
breast cancer has been found suggestive of being aﬀected by
the status of the oncosuppressor proteins p53 [37, 38]. In
71 human primary breast carcinomas with a mutated p53,
as studied by Trer´ e et al. [38], the mean AgNOR area was
greater than in 272 tumors with a normal (wild-type) p53.
Therefore, we think that the type of P53 may play a role in
the mean AgNOR count.
Although HER2/neu did not show any correlation with
AgNORs in the present study, the study by B´ ankfalvi et al.
[39] indicated conﬂicting ﬁndings, which might be attrib-
uted to our criteria for considering the positive results.
They applied immunohistochemistry (IHC) using theA0485
and CB11 antibodies and ﬂuorescence in situ hybridisation
(FISH) for detection of HER2 in 74 routinely processed
breast carcinoma specimens. The rapidity of cellular prolif-
eration was assessed by standardised AgNOR analysis and
compared with HER2 status. Protein overexpression was
found in 30/74 cases by A0485 and in 20/74 by CB11
antibodies, while ampliﬁcation was detected in 22/74 carci-
nomas by FISH. Twenty-seven of 74 tumors were high-level
AgNOR expressors (mean AgNOR area >3.369 microm2),
19 of which revealed ampliﬁcation. They concluded that the
AgNOR analysis may represent an additional tool to selectPathology Research International 5
patientsascandidatesforHerceptintherapyduetothestrong
negative predictor value.
5. Conclusion
We conclude that mean AgNOR counts correlate with
markers of increased malignant potential in breast carci-
nomas. However, AgNORs seem to reﬂect proliferation-
independent cellular and nucleolar activity of tumor cells,
as well. We recommend the use of AgNOR analysis for
prediction of positive or negative expression of ER, PR, and
P53 in routine paraﬃn sections, particularly in low-income
countries, where some of these markers may be unavailable
in routine histopathology.
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